Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). 1992

P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
Department of Clinical Genetics, University Hospital, Lund, Sweden.

Most myxoid liposarcomas (MLS) are characterized cytogenetically by a t(12;16)(q13;p11). It is reasonable to assume that this translocation corresponds to the consistent rearrangement of one or two genes in 12q13 and/or 16p11, and that the loci thus affected are important in the normal control of fat cell differentiation and proliferation. We have used Southern blot technique to test whether a gene of the CCAAT/enhancer binding protein (C/EBP) family, CHOP, which maps to 12q13 and is assumed to be involved in adipocyte differentiation, could be the 12q gene in question. Using a cDNA probe that spans the CHOP coding region, we detected one rearranged and one wild type allele in nine of nine MLS with t(12;16). Using PCR generated, site-specific probes corresponding to the non-coding exons 1 and 2 and intron 2 of CHOP, rearrangements in five of seven tumors mapped to the 2.4 and 1.6 kbp PstI fragments that contain the first two exons and introns of the gene and the upstream promoter region. In contrast to the findings in MLS, no tumor without a t(12;16) exhibited aberrant CHOP restriction digest patterns. These tumors included one highly differentiated liposarcoma with abnormal karyotype but no involvement of 12q13, seven lipomas with various cytogenetic aberrations of 12q13-15, two uterine leiomyomas with t(12;14) (q14-15;q23-24), and one hemangiopericytoma and one chondroma, both of which also had 12q13 changes.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008080 Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed) Liposarcoma, Dedifferentiated,Liposarcoma, Pleomorphic,Atypical Lipomatous Tumor,Liposarcoma, Well Differentiated,Well Differentiated Liposarcoma,Atypical Lipomatous Tumors,Dedifferentiated Liposarcoma,Dedifferentiated Liposarcomas,Lipomatous Tumor, Atypical,Liposarcomas,Pleomorphic Liposarcoma,Pleomorphic Liposarcomas,Well Differentiated Liposarcomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002881 Chromosomes, Human, Pair 12 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 12
D002885 Chromosomes, Human, Pair 16 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 16

Related Publications

P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
December 1986, Cancer genetics and cytogenetics,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
January 1995, Cancer research,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
October 1989, Japanese journal of cancer research : Gann,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
August 2012, Korean journal of pathology,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
January 1987, Oncogene research,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
December 1990, Cancer research,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
February 1995, Cancer genetics and cytogenetics,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
August 2000, The Journal of molecular diagnostics : JMD,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
June 1993, Cancer genetics and cytogenetics,
P Aman, and D Ron, and N Mandahl, and T Fioretos, and S Heim, and K Arheden, and H Willén, and A Rydholm, and F Mitelman
June 1993, Nature genetics,
Copied contents to your clipboard!